N/A
Manufactured by Amarin Pharma Inc.
18,725 FDA adverse event reports analyzed
Last updated: 2026-04-14
ICOSAPENT ETHYL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amarin Pharma Inc.. The most commonly reported adverse reactions for ICOSAPENT ETHYL include PRODUCT ODOUR ABNORMAL, PRODUCT PHYSICAL ISSUE, OFF LABEL USE, DIARRHOEA, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ICOSAPENT ETHYL.
Out of 7,788 classified reports for ICOSAPENT ETHYL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 18,725 FDA FAERS reports that mention ICOSAPENT ETHYL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PRODUCT ODOUR ABNORMAL, PRODUCT PHYSICAL ISSUE, OFF LABEL USE, DIARRHOEA, DRUG INEFFECTIVE, POOR QUALITY PRODUCT ADMINISTERED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Amarin Pharma Inc. in connection with ICOSAPENT ETHYL. Always verify the specific product and NDC with your pharmacist.